MELBOURNE researchers have uncovered a pathway that controls whether bones get stronger or weaker, a breakthrough they hope will lead to the first cure for osteoporosis.
More than a million Australians suffer from the debilitating brittle bone condition, in which bone mass is lost quicker than the body can replace it.
St Vincent’s Institute of Medical Research’s bone cell biology and disease unit has found that by deleting a particular receptor in the bone-forming cells of animals, they can create low bone mass and cause defects in collagen, leaving the bones more susceptible to breakage.
Lead researcher Associate Professor Natalie Sims said after proving this concept, the results of which were published in the Journal of Bone and Mineral Research, they would now focus on shifting the balance of proteins the other way, aiming to improve bone strength.
Prof Sims said the research, backed by a $626,000 grant from the National Health and Medical Research Council, would focus on two proteins, STAT3 and STAT1, which were being investigated around the world in cancer and immunology research.
“We think that if the balance is in favour of STAT3, we will get increased bone formation. But if the balance is shifted the other way, we will get increased bone destruction,” Prof Sims said.
“At the moment there are new treatments based on STAT3 and STAT1 inhibitors and activators that are being used for cancer in preclinical trials.
“We’ll know whether they’ll actually be useful for treating bone disease as well, or whether their use for cancer will have good or bad effects on the skeleton.”
The Latest on: Osteoporosis
via Google News
The Latest on: Osteoporosis
- Geochemistry test can identify osteoporosis earlier than current 'gold-standard' teston June 26, 2020 at 4:19 am
In a novel collaboration, clinicians and geochemists have developed a test that can show the presence of osteoporosis before it has a noticeable clinical effect on bones. The methods are still being ...
- Osteoporosis Drugs Market Size Worth $10.9 Billion By 2026 - KBV Researchon June 26, 2020 at 3:14 am
According to a new report Global Osteoporosis Drugs Market, published by KBV research, The Global Osteoporosis Drugs Market size is expected to reach $10.9 billion by 2026, rising at a market growth ...
- Study sees 'probable' higher heart risk for new Amgen osteoporosis drugon June 24, 2020 at 4:02 pm
An observational study of Amgen Inc's new osteoporosis drug Evenity released on Wednesday appears to confirm the increased risk of serious heart problems detected in clinical trials and included in ...
- Osteoporosis Treatment Market by Product, Route Of Administration, Distribution Channel & Geography | Industry Trends and Forecast to 2026on June 24, 2020 at 4:53 am
Osteoporosis Treatment Market Report has recently added by Value Market Research, this surveillance report establishing the facts based on current scenarios, historical records from 2019 to future ...
- Scientists develop a biodegradable alloy for bone implants for fractures, osteoporosis and myelomaon June 19, 2020 at 7:18 am
Material scientists from NUST MISIS and the University of Western Australia have presented an innovative bioresorbable alloy based on magnesium, gallium and zinc. The material can be used for the ...
- Osteoporosis Drug Shows Promise in Fighting Coronaviruson June 18, 2020 at 8:44 pm
A European research consortium announced Thursday that a supercomputers had identified an existing osteoporosis drug has the potential to be a "promising" treatment for COVID-19.
- Osteoporosis drug shows promise against coronaviruson June 18, 2020 at 11:18 am
EU-backed researchers are requesting clinical trials to study the osteoporosis drug Raloxifene after virtual and laboratory tests suggest it could be active against the COVID-19 virus. The research ...
- Serum hepcidin level, iron metabolism and osteoporosis in patients with rheumatoid arthritison June 18, 2020 at 8:20 am
Hepcidin, a major regulator of iron metabolism and homeostasis, is regulated by inflammation. Recent studies have suggested that hepcidin and iron metabolism are involved in osteoporosis, and the aim ...
- New Capture the Fracture® Partnership Aims for 25% Reduction in the Incidence of Hip and Vertebral Fractures Due to Osteoporosis by 2025on June 16, 2020 at 5:00 am
PRNewswire/ -- The International Osteoporosis Foundation (IOF) has today announced a partnership with Amgen and UCB, in collaboration with the University ...
- Romosozumab offers considerable added benefit for postmenopausal women with osteoporosison June 15, 2020 at 4:57 pm
Romosozumab is a bone-forming monoclonal antibody used in women after menopause for the treatment of severe osteoporosis if there is a high risk of bone fractures.
via Bing News